Board Leadership
-
Amrize Board of Directors Shake-Up
Amrize has appointed Robert S. Rivkin as Chair of its Audit Committee and added Holli Ladhani as a financial expert. These changes aim to enhance audit oversight and support strategic growth. Theresa Drew has resigned from the Board. This follows a strong 2024 performance and positions Amrize for continued expansion in the building materials sector.
-
Mesoblast Board of Directors Appoints New Leadership
Mesoblast is transitioning to commercialization with board leadership changes. Jane Bell steps down as Chair but remains a director, while Philip Facchina assumes the Chair role. Lyn Cobley will lead the Audit and Risk Committee. These changes aim to strengthen U.S. commercial capabilities and drive shareholder value as Mesoblast focuses on market engagement for its cellular medicines, including Ryoncil®.
